Zobrazeno 1 - 10
of 178
pro vyhledávání: '"Takeshi Horai"'
Autor:
Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Shinya Uematsu, Takahiro Yoshizawa, Tsukasa Hasegawa, Ryo Ariyasu, Ken Uchibori, Noriko Yanagitani, Takeshi Horai, Masahiro Seike, Akihiko Gemma, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 11, Iss 9, Pp 2465-2472 (2020)
Background The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/
Externí odkaz:
https://doaj.org/article/52ac1335a6924809921091695f061bbe
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Autor:
Tsukasa Hasegawa, Ryo Ariyasu, Masahiro Seike, Makoto Nishio, Takeshi Horai, Hiroshi Yoshida, Noriko Yanagitani, Akihiko Gemma, Ken Uchibori, Takehiro Tozuka, Satoru Kitazono, Yoshiaki Amino, Takahiro Yoshizawa, Hiroaki Sakamoto, Shinya Uematsu
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 9, Pp 2465-2472 (2020)
Thoracic Cancer, Vol 11, Iss 9, Pp 2465-2472 (2020)
Background The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/
Autor:
Takahiro Yoshizawa, Tsukasa Hasegawa, Kazuo Kasahara, Shinya Uematsu, Takeshi Horai, Makoto Nishio, Satoru Kitazono, Ken Uchibori, Noriko Yanagitani, Atsushi Horiike, Yoshiaki Amino
Publikováno v:
International Journal of Clinical Oncology. 25:67-73
Chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Recently, anti-PD-1 antibody therapy became a key treatment for stage IV NSCLC as the combination of immune checkpoint inhibitors (ICIs) and pl
Autor:
Akihiko Gemma, Ken Uchibori, Takeshi Horai, Takehiro Tozuka, Masahiro Seike, Atsushi Horiike, Noriko Yanagitani, Hiroshi Yoshida, Yoshiaki Amino, Makoto Nishio, Takahiro Yoshizawa, Hiroaki Sakamoto, Shinya Uematsu, Satoru Kitazono, Tsukasa Hasegawa
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Background Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the present study was to evaluate the frequency and prognosis of DR in non-small cell lu
Autor:
Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Shinya Uematsu, Takahiro Yoshizawa, Tsukasa Hasegawa, Ken Uchibori, Noriko Yanagitani, Atsushi Horiike, Takeshi Horai, Masahiro Seike, Akihiko Gemma, Makoto Nishio
Background Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the present study was to evaluate the frequency and prognosis of DR in non-small cell lu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e390dee4a6d879fe7c5bcefd540358d0
https://doi.org/10.21203/rs.2.16868/v3
https://doi.org/10.21203/rs.2.16868/v3
Autor:
Akihiko Gemma, Ken Uchibori, Shinya Uematsu, Masahiro Seike, Takahiro Yoshizawa, Takeshi Horai, Makoto Nishio, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Tsukasa Hasegawa, Takehiro Tozuka, Ryo Ariyasu, Noriko Yanagitani, Satoru Kitazono
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 144
Objectives : Docetaxel (DTX) efficacy increases in patients with non-small cell lung cancer (NSCLC) who had received anti-programmed cell death-1/ligand 1 (anti-PD-1/L1) therapy. However, the effect of ramucirumab (Ram) on DTX efficacy following anti
Autor:
Hiroshi Yoshida, Ken Uchibori, Noriko Yanagitani, Kazuyoshi Kuwano, Hirofumi Utsumi, Makoto Nishio, Yoshiaki Amino, Takahiro Yoshizawa, Takehiro Tozuka, Takeshi Horai, Hiroaki Sakamoto, Hiroshi Wakui, Shinya Uematsu, Tsukasa Hasegawa, Satoru Kitazono, Atsushi Horiike
Publikováno v:
Anticancer research. 39(12)
Background This study aimed to determine whether the neutrophil-to-lymphocyte ratio (NLR) reflected poor treatment benefits in patients with tumor proportion score (TPS) ≥50% and who under went first-line pembrolizumab monotherapy. Patients and met
Autor:
Takeshi Uenami, Makoto Nishio, Atsushi Horiike, Yuko Kawano, Kengo Takeuchi, Yuichi Ishikawa, Noriko Yanagitani, Fumiyoshi Ohyanagi, Azusa Tanimoto, Kyohei Kaburaki, Yuichi Tambo, Takeshi Horai, Keita Kudo, Noriko Motoi
Publikováno v:
Lung Cancer. 93:43-46
Background RET fusions were recently identified in non-small cell lung cancer (NSCLC) and are considered as a potential therapeutic target of NSCLC. Sorafenib, a multi-kinase inhibitor, has potent anti- RET activity. We conducted a study to evaluate
Autor:
Yoshiaki Amino, Takeshi Horai, Noriko Yanagitani, Shinya Uematsu, Makoto Nishio, Tsukasa Hasegawa, Takehiro Tozuka, Hiroaki Sakamoto, Takahiro Yoshizawa, Ryo Ariyasu, Ken Uchibori, Hiroshi Yoshida, Satoru Kitazono
Publikováno v:
Journal of Clinical Oncology. 38:e14511-e14511
e14511 Background: The efficacy of anti-programmed cell death-1/ligand 1 (anti-PD-(L)1) for active brain metastases (BMs) is not established, because most clinical trials excluded patients (pts) with active BMs such as untreated, symptomatic, or unst